Delta Lloyd’s Alexion Pharmaceuticals ALXN Stock Holding History

Delta Lloyd’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-15,677	Closed	-$1.92M	–	636
2016 Q3	$1.92M	Hold	15,677	–	–	0.06%	247
2016 Q2	$1.83M	Hold	15,677	–	–	0.06%	238
2016 Q1	$2.18M	Sell	15,677 -599	-4%	-$88K	0.07%	203
2015 Q4	$3.1M	Buy	16,276 +59	+0.4%	+$10.3K	0.11%	151
2015 Q3	$2.54M	Buy	16,217 +2,458	+18%	+$448K	0.08%	193
2015 Q2	$2.49M	Buy	13,759 +5,088	+59%	+$878K	0.08%	195
2015 Q1	$1.5M	Hold	8,671	–	–	0.05%	222
2014 Q4	$1.6M	Hold	8,671	–	–	0.05%	213
2014 Q3	$1.44M	Buy	8,671 +978	+13%	+$161K	0.01%	216
2014 Q2	$1.2M	Buy	7,693 +991	+15%	+$156K	0.04%	229
2014 Q1	$1.02M	Sell	6,702 -190	-3%	-$30.2K	0.03%	231
2013 Q4	$916K	Sell	6,892 -63,398	-90%	-$7.61M	0.03%	240
2013 Q3	$8.16M	Sell	70,290 -15,950	-18%	-$1.75M	0.31%	69
2013 Q2	$7.96M	Buy	+86,240	New	+$8.31M	0.31%	71

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Delta Lloyd's ALXN Position: Q4 2016 in Review

Delta Lloyd sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 15,677 shares — an estimated $1.92M sold.

Delta Lloyd first reported a position in ALXN in Q2 2013 and held it in 14 quarters. The position peaked at $8.16M in Q3 2013. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

Delta Lloyd reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Delta Lloyd sold 15,677 Alexion Pharmaceuticals shares in Q4 2016, an estimated $1.92M.
Delta Lloyd first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Delta Lloyd's Alexion Pharmaceuticals position peaked at $8.16M in Q3 2013.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Delta Lloyd's 13F filing for Q4 2016, filed 2 Feb 2017.